Recent News

• 05.31.2026 - Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
• 05.31.2026 - Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
• 05.31.2026 - Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
• 05.22.2026 - Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
• 05.13.2026 - Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress
• 05.12.2026 - Ascentage Pharma to Participate in Three Upcoming Investor Conferences

Recent Filings

• 06.01.2026 - EX-99.1 EX-99.1
• 06.01.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.28.2026 - EX-99.1 EX-99.1
• 05.28.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.28.2026 - EX-99.1 EX-99.1
• 05.28.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2026 - EX-99.1 EX-99.1
• 05.22.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]